𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Contemporary brachytherapy approaches in non–small-cell lung cancer

✍ Scribed by Hilaris, Basil S.; Mastoras, Dina A.

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
113 KB
Volume
69
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Brachytherapy has the ability to deliver a higher tumor dose compared to external beam irradiation, while sparing normal tissue outside the tumor; it is the most effective means of delivering conformal radiation and can be tailored to clinical circumstances, either at open surgery or in an ambulatory setting, which is currently the preferred method. Intraoperative lung and/or endobronchial brachytherapy in the management of non-small-cell lung cancer offers a good curative potential in patients with accessible localized tumors, well defined and small to moderate in size, that have not metastasized to the lymph nodes and are technically or medically inoperable. Effective palliation can be frequently obtained by endobronchial brachytherapy on an outpatient procedure basis. Brachytherapy administered simultaneously with chemotherapy is better tolerated than a course of external beam irradiation and chemotherapy.

📜 SIMILAR VOLUMES

Disruption of the RB pathway and cell-pr
Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers
✍ Hisaichi Tanaka; Yoshitaka Fujii; Hirohisa Hirabayashi; Shinichiro Miyoshi; Masa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 407 KB 👁 1 views

The pathway consisting of retinoblastoma protein (pRB), cyclin D1 and p16 (RB pathway) which is involved in the phosphorylation of pRB plays an important role in G 1 /S progression. The disruption of this RB pathway has been reported in several types of human neoplasm. An immunohistochemical study o

Cyclin D1 and retinoblastoma susceptibil
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer
✍ Antonio Marchetti; Claudio Doglioni; Mattia Barbareschi; Fiamma Buttitta; Silvia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 256 KB 👁 1 views

Among the major regulators of the G 1 restriction point are cyclin D1 and the retinoblastoma gene product (RB). In non-small cell lung cancer (NSCLC), the cyclin D1 gene is amplified/over-expressed in almost 50% of cases, and RB is inactivated in 6-32% of cases. It is of interest to evaluate concurr